Cite

HARVARD Citation

    Savarirayan, R. et al. (2022). Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. Therapeutic advances in musculoskeletal disease. p. . [Online]. 
  
Back to record